The Food and Drug Administration silenced one of its drug experts whoraised safety concerns weeks before Merck & Co. yanked theblockbuster drug Vioxx due to increased risks for heart attack andstrokes, the chairman of the Senate Finance Committee said Thursday.
Seven weeks before Merck & Co. pulled the arthritis drug Vioxxoff the market because of safety concerns, federal drug regulatorsdownplayed the significance of scientific findings citing theincreased risks, documents released Thursday show.
Dr. David Graham, associate director for science in the drug safetydivision of the Food and Drug Administration, by early August hadnotified his supervisors that a study of Vioxx showed patients on thestarting dose had 50 percent greater risk of cardiac arrest thanthose on competitor Celebrex.
